Kyverna became the first company this month to initiate a BLA for CAR-T to treat an autoimmune condition. CEO Warner Biddle describes Stiff Person Syndrome and what it means as PoC

2 hours ago
1 min read

He discusses the data from the registrational trial that was presented at AAN last month, and the timeline of the BLA. Plus, myasthenia gravis, which is already in a pivotal, and other conditions the company is considering.

Recent Posts

See All

Sutro Biopharma is developing next generation antibody-drug conjugates, including dual payload ADCs. CEO Jane Chung walks us through their programs

RBC Global Healthcare Conference: With clinical validation that has been seen on the target from a large pharma, Contineum has moved its LPA1R antagonist aggressively into the clinic for IPF

RBC Global Healthcare Conference: Rubedo Life Sciences is the first company to be in the clinic with an GPX4 modulator. They are announcing data today for the first time in actinic keratosis

Kyverna became the first company this month to initiate a BLA for CAR-T to treat an autoimmune condition. CEO Warner Biddle describes Stiff Person Syndrome and what it means as PoC

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight